<DOC>
	<DOCNO>NCT00311701</DOCNO>
	<brief_summary>This retrospective study conduct Canada US involve chart review ass safety oseltamivir ( TamifluÂ® ) compare alternate antiviral therapy , amantidine rimantidine , administer child less 12 month age diagnose suspected influenza . The objective describe frequency neurological adverse event possibly relate administration antiviral infant . Investigators also compare frequency adverse event various dos oseltamivir child . Critical endpoint collect include frequency severity adverse event , particularly relate central nervous system complication . A sub-investigator travel participate site collect data relate infant 's health prior become ill , health status time influenza diagnosis , dose regimen , report neurological event post-dosing , report adverse event post-dosing .</brief_summary>
	<brief_title>Chart Review Antivirals Influenza Infants</brief_title>
	<detailed_description>The study retrospective review chart child le 12 month age diagnose influenza treat oseltamivir . The chart review focus assessment neurological adverse event may relate administration oseltamivir . A control population consist child less 12 month treat either rimantadine amantadine . The administration oseltamivir child high risk ( i.e . immunocompromised host ) less 12 month old influenza frequently consider medical practice despite finding neurotoxicity juvenile rat study . Since oseltamivir active treatment H5N1 influenza strain , imperative understand ramification potential widespread use young infant event outbreak . This study design gather document evidence circumstance use define outcome describe . Patient selection make review hospital inpatient medical record , emergency room medical record and/or pharmacy record identify patient less 1 yr old dose oseltamivir suspension . Redacting chart do manner obscure personal health information ( individual identifier ) without obscure necessary clinical data . A separate research data collection form prepare critical information transcribed would subsequently available analysis . Critical information capture time initiate oseltamivir treatment include : age , birth history , gender , underlie medical condition , present influenza symptom , do , type flu test dose regime . Critical endpoint collect include frequency severity adverse event , particularly relate central nervous system complication .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>1 . Male female study participant less 12 month age 2 . Suspected laboratory diagnosis influenza 3 . Treated oseltamivir , rimantadine amantadine None list</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>11 Months</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Influenza , pediatric</keyword>
</DOC>